Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A carcinoma that arises from epithelial cells of the gall bladder
Biomarker and diagnostic research for gallbladder carcinoma has been reported in the published literature.
47 clinical trials registered, 18 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 2 PHASE3, 20 PHASE2, 6 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06423170](https://clinicaltrials.gov/study/NCT06423170) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 1:57 AM UTC
A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs |
PHASE2 |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
RECRUITING |
[NCT04907643](https://clinicaltrials.gov/study/NCT04907643) | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | NA | Cedars-Sinai Medical Center | RECRUITING |
[NCT06123117](https://clinicaltrials.gov/study/NCT06123117) | STALL vs Sole Local Wound Infiltration in Laparoscopic Cholecystectomy | NA | Helsinki University Central Hospital | RECRUITING |
[NCT05757336](https://clinicaltrials.gov/study/NCT05757336) | Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer | PHASE2 | Lu Wang, MD, PhD | RECRUITING |
[NCT07146646](https://clinicaltrials.gov/study/NCT07146646) | Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer | PHASE2 | Case Comprehensive Cancer Center | RECRUITING |
371 publications have been identified in PubMed for gallbladder carcinoma. Kisho has analyzed 222 by research type. Research spans Case Report / Case Series (23%), Diagnostic / Biomarker (20%), and Review / Meta-Analysis (19%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 50 | 23% |
Testing and diagnosis research | 44 | 20% |
Research summaries | 42 | 19% |
Laboratory research | 31 | 14% |
Disease patterns and progression | 31 | 14% |
Clinical study results | 16 | 7% |
Other research | 4 | 2% |
New treatment approaches | 4 | 2% |
Zheng Q (2026). [PMID: 40967375](https://pubmed.ncbi.nlm.nih.gov/40967375/). *Int J Radiat Oncol Biol Phys*. [Epidemiology / Natural History]
Gupta A (2026). [PMID: 41694872](https://pubmed.ncbi.nlm.nih.gov/41694872/). *Cureus*. [Case Report / Case Series]
Fu Z (2026). [PMID: 41512870](https://pubmed.ncbi.nlm.nih.gov/41512870/). *Cancer Cell*. [Basic Science / Preclinical]
Angerilli V (2026). [PMID: 42103452](https://pubmed.ncbi.nlm.nih.gov/42103452/). *J Clin Pathol*. [Other]
Varshney VK (2026). [PMID: 41779281](https://pubmed.ncbi.nlm.nih.gov/41779281/). *J Gastrointest Cancer*. [Review / Meta-Analysis]
Singh N (2026). [PMID: 42220667](https://pubmed.ncbi.nlm.nih.gov/42220667/). *Cureus*. [Diagnostic / Biomarker]
Vineet K (2026). [PMID: 41724874](https://pubmed.ncbi.nlm.nih.gov/41724874/). *J Gastrointest Cancer*. [Epidemiology / Natural History]
Szvarca D (2026). [PMID: 42270518](https://pubmed.ncbi.nlm.nih.gov/42270518/). *Hematol Oncol Clin North Am*. [Review / Meta-Analysis]
Sahani P (2026). [PMID: 42209821](https://pubmed.ncbi.nlm.nih.gov/42209821/). *Discov Oncol*. [Epidemiology / Natural History]
Shechter S (2026). [PMID: 41691732](https://pubmed.ncbi.nlm.nih.gov/41691732/). *Eur J Radiol*. [Basic Science / Preclinical]